These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 12694309)

  • 1. Vasopeptidase inhibition: a new treatment approach for endothelial dysfunction.
    Quaschning T; Galle J; Wanner C
    Kidney Int Suppl; 2003 May; (84):S54-7. PubMed ID: 12694309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vasopeptidase inhibition: effective blood pressure control for vascular protection.
    Quaschning T; Ruschitzka F; Lüscher TF
    Curr Hypertens Rep; 2002 Feb; 4(1):78-84. PubMed ID: 11790296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vasopeptidase inhibition for blood pressure control: emerging experience.
    Quaschning T
    Curr Pharm Des; 2005; 11(25):3293-9. PubMed ID: 16250856
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vasopeptidase inhibitors: a new therapeutic concept in cardiovascular disease?
    Corti R; Burnett JC; Rouleau JL; Ruschitzka F; Lüscher TF
    Circulation; 2001 Oct; 104(15):1856-62. PubMed ID: 11591626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vasopeptidase inhibition: a new concept in blood pressure management.
    Burnett JC
    J Hypertens Suppl; 1999 Feb; 17(1):S37-43. PubMed ID: 10340842
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vasopeptidase inhibitors, neutral endopeptidase inhibitors, and dual inhibitors of angiotensin-converting enzyme and neutral endopeptidase.
    Nawarskas J; Rajan V; Frishman WH
    Heart Dis; 2001; 3(6):378-85. PubMed ID: 11975822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vasopeptidase inhibition: a double-edged sword?
    Campbell DJ
    Hypertension; 2003 Mar; 41(3):383-9. PubMed ID: 12623931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Towards triple vasopeptidase inhibitors for the treatment of cardiovascular diseases.
    Daull P; Jeng AY; Battistini B
    J Cardiovasc Pharmacol; 2007 Sep; 50(3):247-56. PubMed ID: 17878751
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vasopeptidase inhibitors: will they have a role in clinical practice?
    Worthley MI; Corti R; Worthley SG
    Br J Clin Pharmacol; 2004 Jan; 57(1):27-36. PubMed ID: 14678337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vasopeptidase inhibitors: potential role in the treatment of heart failure.
    Trindade PT; Rouleau JL
    Heart Fail Monit; 2001; 2(1):2-7. PubMed ID: 12634892
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vasopeptidase inhibition and endothelial function in hypertension.
    d'Uscio LV; Lüscher TF
    Curr Hypertens Rep; 2001 Dec; 3 Suppl 2():S6-14. PubMed ID: 11716800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of omapatrilat on pharmacodynamic biomarkers of neutral endopeptidase and Angiotensin-converting enzyme activity in humans.
    Vesterqvist O; Reeves RA
    Curr Hypertens Rep; 2001 Dec; 3 Suppl 2():S22-7. PubMed ID: 11716802
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of neutral endopeptidase inhibition and combined angiotensin converting enzyme and neutral endopeptidase inhibition on angiotensin and bradykinin peptides in rats.
    Campbell DJ; Anastasopoulos F; Duncan AM; James GM; Kladis A; Briscoe TA
    J Pharmacol Exp Ther; 1998 Nov; 287(2):567-77. PubMed ID: 9808682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vasopeptidase inhibition: a novel approach to cardiovascular therapy.
    Floras JS
    Can J Cardiol; 2002 Feb; 18(2):177-82. PubMed ID: 11875587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current role of neprilysin inhibitors in hypertension and heart failure.
    von Lueder TG; Atar D; Krum H
    Pharmacol Ther; 2014 Oct; 144(1):41-9. PubMed ID: 24836726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of neutral endopeptidase causes vasoconstriction of human resistance vessels in vivo.
    Ferro CJ; Spratt JC; Haynes WG; Webb DJ
    Circulation; 1998 Jun; 97(23):2323-30. PubMed ID: 9639376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Triple vasopeptidase inhibition normalizes blood pressure in conscious, unrestrained, and spontaneously hypertensive rats.
    Daull P; Benrezzak O; Arsenault D; Pheng LH; Blouin A; Cayer J; Beaudoin M; Belleville K; Sirois P; Nantel F; Jeng AY; Battistini B
    Am J Hypertens; 2005 Dec; 18(12 Pt 1):1606-13. PubMed ID: 16364833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cell surface metallopeptidases involved in blood pressure regulation: structure, inhibition and clinical perspectives.
    Roques BP
    Pathol Biol (Paris); 1998 Mar; 46(3):191-200. PubMed ID: 9769915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In-vitro and in-vivo inhibition of rat neutral endopeptidase and angiotensin converting enzyme with the vasopeptidase inhibitor gemopatrilat.
    Hubner RA; Kubota E; Casley DJ; Johnston CI; Burrell LM
    J Hypertens; 2001 May; 19(5):941-6. PubMed ID: 11393678
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vasopeptidase inhibition with omapatrilat increases fluid and protein microvascular permeability in cat skeletal muscle.
    Persson J; Morsing P; Grände PO
    J Hypertens; 2004 Mar; 22(3):637-44. PubMed ID: 15076171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.